Data Insights

Pembrolizumab by Merck for Urethral Cancer: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase III for Urethral Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Urethral Cancer

Data Insights

Pembrolizumab by Merck for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase III for Muscle Invasive Bladder Cancer (MIBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Muscle Invasive Bladder Cancer (MIBC)

Data Insights

Pembrolizumab by Merck for Metastatic Liver Cancer: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Metastatic Liver Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Metastatic Liver Cancer

Data Insights

Pembrolizumab by Merck for Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer of Unknown Primary): Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer of Unknown Primary)

Data Insights

Pembrolizumab by Merck for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Recurrent Glioblastoma Multiforme (GBM)

Data Insights

Pembrolizumab by Merck for Gliosarcoma: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Gliosarcoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Gliosarcoma

Data Insights

Pembrolizumab by Merck for Uterine Cancer: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase I for Uterine Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Uterine Cancer

Data Insights

Pembrolizumab by Merck for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Adrenocortical Carcinoma (Adrenal Cortex Cancer)

Data Insights

Pembrolizumab by Merck for Kaposi Sarcoma: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase I for Kaposi Sarcoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Kaposi Sarcoma

Data Insights

Pembrolizumab by Merck for Bladder Cancer: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase III for Bladder Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Bladder Cancer

Data Insights

Pembrolizumab by Merck for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Marginal Zone B-cell Lymphoma

Data Insights

Pembrolizumab by Merck for Metastatic Liver Cancer: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Metastatic Liver Cancer. According to GlobalData, Phase...

Data Insights

Pembrolizumab by Merck for Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer of Unknown Primary): Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer...

Data Insights

Pembrolizumab by Merck for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData,...

Data Insights

Pembrolizumab by Merck for Gliosarcoma: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Gliosarcoma. According to GlobalData, Phase II drugs...

Data Insights

Pembrolizumab by Merck for Uterine Cancer: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase I for Uterine Cancer. According to GlobalData, Phase I...

Data Insights

Pembrolizumab by Merck for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According to...

Data Insights

Pembrolizumab by Merck for Kaposi Sarcoma: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase I for Kaposi Sarcoma. According to GlobalData, Phase I...

Data Insights

Pembrolizumab by Merck for Bladder Cancer: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase III for Bladder Cancer. According to GlobalData, Phase III...

Data Insights

Pembrolizumab by Merck for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...